Alnylam Pharmaceuticals
ALNY
#378
Rank
HK$471.15 B
Marketcap
HK$3,566
Share price
-1.55%
Change (1 day)
78.88%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : HK$35.94 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are HK$35.94 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31HK$32.39 B2.41%
2023-12-31HK$31.63 B9.29%
2022-12-31HK$28.94 B21.5%
2021-12-31HK$23.82 B28.53%
2020-12-31HK$18.53 B148.82%
2019-12-31HK$7.44 B248.64%
2018-12-31HK$2.13 B19.78%
2017-12-31HK$1.78 B-32.86%
2016-12-31HK$2.65 B181.42%
2015-12-31HK$0.94 B-15.09%
2014-12-31HK$1.11 B-4.54%
2013-12-31HK$1.16 B-2.1%
2012-12-31HK$1.18 B-6.57%
2011-12-31HK$1.27 B-30.39%
2010-12-31HK$1.82 B-22.25%
2009-12-31HK$2.35 B-13.64%
2008-12-31HK$2.72 B18.6%
2007-12-31HK$2.29 B660.61%
2006-12-31HK$0.30 B6.52%
2005-12-31HK$0.28 B82.74%
2004-12-31HK$0.15 B-67.66%
2003-12-31HK$0.47 B196.36%
2002-12-31HK$0.16 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Arrowhead Pharmaceuticals
ARWR
HK$6.70 B-81.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
HK$71.70 B 99.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
HK$16.91 B-52.94%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
HK$5.37 B-85.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
HK$45.13 M-99.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
HK$486.82 B 1,254.27%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$513.99 B 1,329.85%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
HK$253.79 B 606.01%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel